Aphrodisiacs

Palatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on February 17, 2021

Retrieved on: 
Friday, February 12, 2021
Aphrodisiacs, Peptides, Bremelanotide, New York Stock Exchange, Conference call, New York City, Service industries

CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 17, 2021 at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Palatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on November 17, 2020

Retrieved on: 
Thursday, November 12, 2020
Aphrodisiacs, Peptides, Bremelanotide, New York Stock Exchange, Conference call, New York City, Service industries

CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 17, 2020 at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 Results; Teleconference and Webcast to be held on September 28, 2020

Retrieved on: 
Thursday, September 24, 2020
Aphrodisiacs, Peptides, New York Stock Exchange, Bremelanotide, Conference call, New York City

CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2020 at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Searchlight Pharma expands its Women's Health Portfolio and initiates Addyi® commercial activities

Retrieved on: 
Wednesday, September 16, 2020
Human sexuality, Aphrodisiacs, Benzimidazoles, Flibanserin, Ureas, Hypoactive sexual desire disorder, Pharmaceutical industry in China, Searchlight

Searchlight Pharma acquired the Canadian rights to Addyi (flibanserin) via its recently executed licensing transaction with Sprout Pharmaceuticals.

Key Points: 
  • Searchlight Pharma acquired the Canadian rights to Addyi (flibanserin) via its recently executed licensing transaction with Sprout Pharmaceuticals.
  • Following just weeks after its recently executed long term licensing agreement with Sprout Pharmaceuticals, Searchlight Pharma will now integrate Addyi into its industry-leading women's health and female sexual health portfolio deploying its national salesforce to promote this novel brand.
  • "We are excited to further grow our women's health portfolio with this first-in-class medication for the treatment of HSDD in Canada," said Mark Nawacki, President and CEO of Searchlight Pharma.
  • We couldn't think of a better partner than Searchlight considering their impressive track record and steadfast commitment to women's health."

Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Retrieved on: 
Thursday, September 10, 2020
Aphrodisiacs, Peptides, Bremelanotide

The conference will be held virtually.

Key Points: 
  • The conference will be held virtually.
  • Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.
  • Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
  • For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com .

Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference

Retrieved on: 
Thursday, August 13, 2020
Aphrodisiacs, Peptides, Branches of biology, Canaccord Genuity, Peptide hormones, Genuity, Bremelanotide, Organ systems, Natriuretic peptide, Melanocortin, Molecular biology

CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40th Annual Growth Conference in a Fireside Chat today at 10:30 am ET.

Key Points: 
  • CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40th Annual Growth Conference in a Fireside Chat today at 10:30 am ET.
  • Carl Spana, Ph.D., President and Chief Executive Officer and Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, participated in the Fireside Chat hosted by John Newman of Canaccord Genuity.
  • Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
  • For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com .

Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®

Retrieved on: 
Monday, July 27, 2020
Aphrodisiacs, Peptides, Bremelanotide, AMAG Automobil- und Motoren, AMAG

Under the terms of the termination agreement, Palatin will regain all North American development and commercialization rights for Vyleesi.

Key Points: 
  • Under the terms of the termination agreement, Palatin will regain all North American development and commercialization rights for Vyleesi.
  • AMAG will make a $12 million payment to Palatin at closing and a $4.3 million payment to Palatin on March 31, 2021.
  • Palatin will assume all Vyleesi manufacturing agreements, and AMAG will transfer all information, data, and assets related exclusively to Vyleesi, including, but not limited to, existing inventory.
  • AMAG will provide certain transitional services to Palatin for a period of time to ensure continued patient access to Vyleesi during the transition back to Palatin.

Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations

Retrieved on: 
Thursday, April 30, 2020
Health, Articles, Peptides, Aphrodisiacs, Bremelanotide, AMAG Pharmaceuticals, Clinical research, Global health, Pharmaceuticals policy, Clinical trial, AMAG, Pandemic

During this pandemic, the safety of Palatin's employees, clinical trial patients and healthcare partners has been the Company's number one priority.

Key Points: 
  • During this pandemic, the safety of Palatin's employees, clinical trial patients and healthcare partners has been the Company's number one priority.
  • Assuming partial opening of economic activities by mid-2020, senior management believes there will be limited impact of the pandemic on operations.
  • Palatin is not responsible for updating for events that occur after the date of this press release.
  • Vyleesi is a registered trademark of AMAG Pharmaceuticals, Inc. in North America and of Palatin Technologies, Inc. elsewhere in the world.

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019

Retrieved on: 
Thursday, November 7, 2019
Peptides, Aphrodisiacs, Bremelanotide, Conference call, New York Stock Exchange

CRANBURY, N.J., Nov. 7, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Nov. 7, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 13, 2019 at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

Retrieved on: 
Wednesday, September 11, 2019
Peptides, Aphrodisiacs, Bremelanotide, New York Stock Exchange, Conference call

CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 12, 2019 at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast